Alder Obtains First Milestone Under BMS Deal, Advances Own Program In Cancer Supportive Care
Privately held biotech earns $15 million as Bristol Myers Squibb readies interleukin-6 inhibitor for Phase IIb dose-ranging trial in rheumatoid arthritis.
Privately held biotech earns $15 million as Bristol Myers Squibb readies interleukin-6 inhibitor for Phase IIb dose-ranging trial in rheumatoid arthritis.